Virtu Financial’s Titan Pharmaceuticals TTNP Stock Holding History

Virtu Financial’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,004	Closed	-$16K	–	2113
2022 Q4	$16K	Sell	1,004 -413	-29%	-$7.81K	﹤0.01%	1309
2022 Q3	$31K	Sell	1,417 -1,700	-55%	-$43.9K	﹤0.01%	1311
2022 Q2	$35K	Buy	+3,117	New	+$38.9K	﹤0.01%	1214
2022 Q1	–	Sell	-771	Closed	-$16K	–	2045
2021 Q4	$16K	Buy	+771	New	+$23.2K	﹤0.01%	1538
2021 Q3	–	Sell	-1,665	Closed	-$87K	–	1974
2021 Q2	$87K	Buy	+1,665	New	+$83.3K	0.01%	1235
2020 Q3	–	Sell	-238	Closed	-$44K	–	1525
2020 Q2	$44K	Buy	+238	New	+$41K	0.01%	1021
2019 Q4	$101K	Buy	868 +810	+1,397%	+$97.6K	0.01%	1084
2019 Q3	$9K	Sell	58 -8	-12%	-$3.61K	﹤0.01%	1358
2019 Q2	$50K	Buy	+66	New	+$60.3K	﹤0.01%	1235
2019 Q1	–	Sell	-66	Closed	-$53K	–	1849
2018 Q4	$53K	Buy	66 +56	+560%	+$62.8K	﹤0.01%	1258
2018 Q3	$8K	Buy	+10	New	+$27.2K	﹤0.01%	1455

Other funds holding TTNP

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

LFA

Level Financial Advisors East Amherst, New York $448M AUM 16.6% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Virtu Financial's TTNP Position: Q1 2023 in Review

Virtu Financial sold out of Titan Pharmaceuticals (TTNP) in Q1 2023, closing a stake of 1,004 shares — an estimated $16K sold.

Virtu Financial first reported a position in TTNP in Q3 2018 and held it in 11 quarters. The position peaked at $101K in Q4 2019. 17 funds tracked by Wall St. Rank hold TTNP as of Q1 2023.

Virtu Financial reported no remaining Titan Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Virtu Financial sold 1,004 Titan Pharmaceuticals shares in Q1 2023, an estimated $16K.
Virtu Financial first reported a position in Titan Pharmaceuticals in Q3 2018 and held it in 11 quarters.
Virtu Financial's Titan Pharmaceuticals position peaked at $101K in Q4 2019.
17 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2023.

Based on Virtu Financial's 13F filing for Q1 2023, filed 1 May 2023.